Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Схожі ресурси

• Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
  за авторством: Passakorn Wanchaijiraboon, та інші
  Опубліковано: (2022-10-01)
• Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
  за авторством: Passakorn Wanchaijiraboon, та інші
  Опубліковано: (2023-02-01)
• Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
  за авторством: Nussara Pakvisal, та інші
  Опубліковано: (2022-11-01)
• Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial
  за авторством: Narawitch Sompornpailin, та інші
  Опубліковано: (2026-06-01)
• Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
  за авторством: Jira Chansaenroj, та інші
  Опубліковано: (2022-07-01)